Form 8-K - Current report:
SEC Accession No. 0000950170-23-008443
Filing Date
2023-03-16
Accepted
2023-03-16 16:05:37
Documents
13
Period of Report
2023-03-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K grph-20230310.htm   iXBRL 8-K 55986
2 EX-10.1 grph-ex10_1.htm EX-10 66643
  Complete submission text file 0000950170-23-008443.txt   253218

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT grph-20230310.xsd EX-101.SCH 2466
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT grph-20230310_lab.xml EX-101.LAB 13904
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT grph-20230310_pre.xml EX-101.PRE 10228
7 EXTRACTED XBRL INSTANCE DOCUMENT grph-20230310_htm.xml XML 4860
Mailing Address 201 HASKINS WAY, SUITE 210 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY, SUITE 210 SOUTH SAN FRANCISCO CA 94080 (650) 484-0886
Graphite Bio, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 23738761
SIC: 2836 Biological Products, (No Diagnostic Substances)